Immune checkpoint inhibitors kill cancer cells by releasing the brakes on the immune system, thereby allowing it to mount an antitumor response. This form of immunotherapy has led to dramatic responses in some patients; however, most patients’ tumors do not respond to immune checkpoint inhibition, and resistance can develop in tumors that initially respond.
The vast majority of participants enrolled in nearly 60 prostate cancer clinical trials were non-Hispanic white men, Harvard researchers report.
A recent study reports that high adherence to oral diabetes medication was associated with improved survival for patients with colorectal cancer.
A recent study shows that testicular cancer rates are increasing for Asian/Pacific Islanders, Hispanics, and American Indians/Alaska Natives.
Findings from a recent study suggest that patients may experience a greater occurrence of infections in the years preceding a cancer diagnosis.
Epithelial ovarian cancer is by far the most common ovarian cancer subtype, accounting for 90 percent of ovarian cancers. The complex genetic heterogeneity of this disease makes treatment particularly difficult. While the introduction of PARP inhibitors to treat ovarian cancers has been a major advancement, only the approximately 50 percent of epithelial ovarian cancers that exhibit defective DNA repair via homologous recombination are potentially responsive to PARP inhibition. Moreover, the development of therapeutic resistance remains a challenge.
A new study suggests that a HER2-targeted therapy approved for breast cancer may be effective for several other cancers. Human epidermal growth factor receptor 2 (HER2) is a protein that can promote cancer progression...
A new study finds that Latina women with a higher proportion of Indigenous American ancestry may be at increased risk of being diagnosed with HER2-positive breast cancer.
Despite concerns that reducing nicotine levels in cigarettes could have unintended effects on smoking behavior, findings from two recent studies suggest that smokers do not smoke more cigarettes or smoke more intensely when using low-nicotine cigarettes.
Due to the high cost of care and cost-sharing, many of the more than 16.9 million survivors in the United States face significant financial challenges. Research-driven progress against cancer has created a growing population...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More